Clinical Research Directory
Browse clinical research sites, groups, and studies.
Equol and Vascular Function in Women With Chronic Kidney Disease
Sponsor: University of Colorado, Denver
Summary
The risk of cardiovascular disease (CVD) is significantly elevated in patients with chronic kidney disease (CKD). Notably, women with CKD commonly experience menstrual disturbances induced by CKD, which may contribute to impaired vascular function and elevated CVD risk. However, most of the literature in nephrology focuses on male patients, and studies on women's vascular health are limited. Establishing effective therapies for improving vascular function and reducing CVD risk in women with CKD is a high research priority of the NIH. Equol contributes to improvement in vascular function, mediated in part by its anti-oxidative and anti-inflammatory properties. However, there is no information on the effect of equol on vascular function in women with CKD. The proposed project aims to determine the effect of 12 weeks of oral equol supplementation on vascular function in postmenopausal women with CKD.
Official title: Equol Supplementation for Improving Vascular Function in Postmenopausal Women With CKD
Key Details
Gender
FEMALE
Age Range
50 Years - Any
Study Type
INTERVENTIONAL
Enrollment
74
Start Date
2025-12-01
Completion Date
2030-11-30
Last Updated
2025-09-26
Healthy Volunteers
No
Conditions
Interventions
Equol
This group will receive 10 mg equol per day (2 capsules/day, 5mg equol/capsule).
Placebo
This group will receive 2 placebo capsules per day.